Latest news with #vVARDIS
Yahoo
6 days ago
- Health
- Yahoo
Over 400,000 Patients Experience Early Intervention Dentistry as vVARDIS and VideaHealth Use AI-Enabled and Non-Invasive Dentistry
AI-powered platform accelerates early-stage caries detection, drill-free treatment, and proactive model for caries management BOSTON, August 05, 2025--(BUSINESS WIRE)--VideaHealth, the leader in AI-powered dental solutions, and vVARDIS, the high-growth oral care company driving a transformation to non-invasive dentistry, are expanding their impact on patient outcomes by focusing AI and non-invasive treatments to elevate the standard of care for caries management. Since launching their commercial collaboration, VideaAI has helped clinicians identify incipient caries, which reflect early-stage decay, and over 400,000 of those patients were treated with Curodont™ Repair Fluoride Plus, a drill-free, same day treatment, helping to preserve natural tooth structure and avoiding an invasive treatment. This is a promising sign that early intervention with a medical approach for caries is gaining traction across the industry. Built on a shared vision of advancing minimally invasive care, the collaboration integrates the VideaAI platform and vVARDIS' Curodont™ into the same workflow — a non-invasive biomimetic treatment backed by numerous scientific publications, including peer reviewed and meta-analysis studies. These tools allow practices to identify early caries with AI precision, educate patients through visualizations, and deliver treatment in the same appointment without a drill or anesthesia. Since deploying VideaAI and Curodont™, practices have reported measurable impacts across key performance and care metrics such as increased patient adoption of treatment of early caries lesions. "We founded VideaHealth to bring clinical clarity and consistency to every dental visit. This partnership demonstrates what's possible when AI is used to strengthen and not replace clinical decision-making," said Florian Hillen, CEO of VideaHealth. "In our collaboration with vVARDIS, we're helping to create a world where early detection and drill-free treatment are the standards rather than the exception." VideaHealth and vVARDIS are also working to close the gap between oral health and whole body wellness. It is widely recognized that poor oral health can impact overall health, and if left untreated, tooth decay can lead to additional health impacts. By leveraging AI to detect and treat early caries, personalize care, and improve transparency, the collaboration aims to build greater trust across the healthcare ecosystem and advance a more streamlined approach to patient health. "We created vVARDIS to bring science, trust, and access back to dentistry," said Dr. Haley and Dr. Goly Abivardi, DMDs, co-founders and co-CEOs of vVARDIS. "The momentum we've seen with VideaHealth confirms what we've always believed; when patients clearly understand their diagnosis, and clinicians are empowered with the right tools, better care can occur. With Curodont™ demonstrating a 90%+ success rate* in treating early caries, it is improving both how and when care is delivered." "This makes it easier to do the right thing faster. We've seen consistent growth in both prevention and production, and most importantly, our clinicians and families trust the process," said Evelyn Lahiji, COO of Children's Dental FunZone. "Curodont™ provides our clinicians with a minimally invasive solution they believe in, and VideaAI helps them pinpoint exactly where it's needed." VideaHealth and vVARDIS remain committed to increasing access, reducing invasiveness, and elevating patient trust. VideaAI is now used by over 50,000 clinicians and is growing, with an eye on transforming dental care into a trusted frontline of public health. For more information about VideaHealth and the use of VideaAI, visit For more information about vVardis and Curodont, visit About VideaHealth VideaHealth is transforming dentistry with AI-powered solutions that help practices elevate care standards, improve productivity, and drive real business value. VideaAI, a comprehensive Dental AI Assistant, supports every aspect of dental care, from diagnostics and workflows to analytics and revenue optimization. Used by more than 50,000 clinicians across 50+ leading DSOs, VideaHealth's FDA-cleared AI analyzes over 500 million X-rays annually, delivering trusted insights that power consistent, high-quality care. Headquartered in Boston and backed by leading investors, VideaHealth is advancing the future of dental care through responsible and real-world AI. Learn more at About vVARDIS Founded in Switzerland by Dr. Haley and Dr. Goly Abivardi, vVARDIS offers innovative biomimetic, non-invasive, dental products to treat early-stage decay. vVARDIS is the result of more than 25 years of research, paired with the commitment of its founders to make an impact on people's lives. For more information, visit *Data on file. View source version on Contacts Media Contact:Brynn 832.671.0733
Business Wire
6 days ago
- Health
- Business Wire
Over 400,000 Patients Experience Early Intervention Dentistry as vVARDIS and VideaHealth Use AI-Enabled and Non-Invasive Dentistry
BOSTON--(BUSINESS WIRE)-- VideaHealth, the leader in AI-powered dental solutions, and vVARDIS, the high-growth oral care company driving a transformation to non-invasive dentistry, are expanding their impact on patient outcomes by focusing AI and non-invasive treatments to elevate the standard of care for caries management. Since launching their commercial collaboration, VideaAI has helped clinicians identify incipient caries, which reflect early-stage decay, and over 400,000 of those patients were treated with Curodont™ Repair Fluoride Plus, a drill-free, same day treatment, helping to preserve natural tooth structure and avoiding an invasive treatment. This is a promising sign that early intervention with a medical approach for caries is gaining traction across the industry. Built on a shared vision of advancing minimally invasive care, the collaboration integrates the VideaAI platform and vVARDIS' Curodont™ into the same workflow — a non-invasive biomimetic treatment backed by numerous scientific publications, including peer reviewed and meta-analysis studies. These tools allow practices to identify early caries with AI precision, educate patients through visualizations, and deliver treatment in the same appointment without a drill or anesthesia. Since deploying VideaAI and Curodont™, practices have reported measurable impacts across key performance and care metrics such as increased patient adoption of treatment of early caries lesions. 'We founded VideaHealth to bring clinical clarity and consistency to every dental visit. This partnership demonstrates what's possible when AI is used to strengthen and not replace clinical decision-making,' said Florian Hillen, CEO of VideaHealth. 'In our collaboration with vVARDIS, we're helping to create a world where early detection and drill-free treatment are the standards rather than the exception.' VideaHealth and vVARDIS are also working to close the gap between oral health and whole body wellness. It is widely recognized that poor oral health can impact overall health, and if left untreated, tooth decay can lead to additional health impacts. By leveraging AI to detect and treat early caries, personalize care, and improve transparency, the collaboration aims to build greater trust across the healthcare ecosystem and advance a more streamlined approach to patient health. 'We created vVARDIS to bring science, trust, and access back to dentistry,' said Dr. Haley and Dr. Goly Abivardi, DMDs, co-founders and co-CEOs of vVARDIS. 'The momentum we've seen with VideaHealth confirms what we've always believed; when patients clearly understand their diagnosis, and clinicians are empowered with the right tools, better care can occur. With Curodont™ demonstrating a 90%+ success rate* in treating early caries, it is improving both how and when care is delivered.' 'This makes it easier to do the right thing faster. We've seen consistent growth in both prevention and production, and most importantly, our clinicians and families trust the process,' said Evelyn Lahiji, COO of Children's Dental FunZone. 'Curodont™ provides our clinicians with a minimally invasive solution they believe in, and VideaAI helps them pinpoint exactly where it's needed.' VideaHealth and vVARDIS remain committed to increasing access, reducing invasiveness, and elevating patient trust. VideaAI is now used by over 50,000 clinicians and is growing, with an eye on transforming dental care into a trusted frontline of public health. For more information about VideaHealth and the use of VideaAI, visit For more information about vVardis and Curodont, visit About VideaHealth VideaHealth is transforming dentistry with AI-powered solutions that help practices elevate care standards, improve productivity, and drive real business value. VideaAI, a comprehensive Dental AI Assistant, supports every aspect of dental care, from diagnostics and workflows to analytics and revenue optimization. Used by more than 50,000 clinicians across 50+ leading DSOs, VideaHealth's FDA-cleared AI analyzes over 500 million X-rays annually, delivering trusted insights that power consistent, high-quality care. Headquartered in Boston and backed by leading investors, VideaHealth is advancing the future of dental care through responsible and real-world AI. Learn more at About vVARDIS Founded in Switzerland by Dr. Haley and Dr. Goly Abivardi, vVARDIS offers innovative biomimetic, non-invasive, dental products to treat early-stage decay. vVARDIS is the result of more than 25 years of research, paired with the commitment of its founders to make an impact on people's lives. For more information, visit *Data on file.
Business Wire
24-07-2025
- Business
- Business Wire
vVARDIS' Drill-Free Solution Curodont ™ Has Treated Over One Million Teeth in 18 Months and Is the Fastest Growing Dental Care Product in Its Category
ZUG, Switzerland--(BUSINESS WIRE)-- vVARDIS, a Swiss high-growth healthcare company, active in the development of innovative dental products, today announced that more than one million teeth and more than 420,000 patients have been treated in the United States since January 2024 with Curodont™, its drill-free solution for early stage tooth decay, making it the fastest growing dental care product in its category i ii. Nearly 80 percent of all dental patients have early tooth decay iii. Oral health is an important aspect of overall health, and poor oral health, including untreated decay, can become life-threatening. With Curodont™, dental teams have a drill-free solution to treat tooth decay at an early stage. Curodont™ represents a true win-win proposition: patients benefit from a quick, needle- and drill-free treatment, while dental professionals can treat early decay within minutes—eliminating the need for a follow-up appointment and freeing up chair time for more complex procedures. 'Now that Curodont™ is available in nearly 10 percent of U.S. dental offices iv, an increasing number of dental professionals – or 'Curodontists' – are embracing our treatment and giving patients access to this revolutionary solution,' said Dr. Haley Abivardi, DMD, co-CE, and co-founder of vVARDIS. 'Such high-speed adoption shows how dental professionals have been waiting for decades for a solution that enables them to treat tooth decay at an early stage.' Dr. Goly Abivardi, DMD, co-CEO and co-founder of vVARDIS, said, 'We are thrilled to witness a ground-breaking transformation in dentistry similar to the advancements that medicine embraced years ago toward non-invasive, early intervention approaches. In the same way, Curodont™ is helping to elevate the standard of care for the early treatment of cavities.' With more than 25 years of science, vVARDIS' Curodont™ is backed by universities internationally and has earned the endorsement of renowned thought leaders, clinical experts, and innovators across the dental profession: Dr. German O. Gallucci, Chair of the Department of Restorative Dentistry and Biomaterials Sciences at Harvard School of Dental Medicine, said, 'Curodont™ is highly effective for treatment of early decays. This new non-invasive therapeutic option is a game changer in the battle against tooth decay.' Prof. Amid I. Ismail, Laura H. Carnell Professor and Dean of the Kornberg School of Dentistry, Temple University, said, 'As an epidemiologist and cariologist who has studied dental caries for over four decades and developed guidelines for its diagnosis and management, I can state without hesitation that the advent of Curodont™ represents a significant breakthrough in caries management.' Dr. Timothy Quirt, DDS, MBA, Senior Vice President, Clinical Operations at Heartland Dental, said, 'Curodont™ represents a transformative step forward in dentistry. At Heartland Dental, we've seen firsthand how this innovation empowers clinicians to treat early-stage caries non-invasively, improving outcomes and deepening patient trust. It's not just a product – it's a shift in how we think about the future of oral health.' Dr. Shan K. Bagby, DMD, MHA, FACHE, Brigadier General, USA (Ret.) has recognized Curodont's™ potential to improve the health of children from lower-income homes, saying, 'What makes Curodont™ especially impactful is its potential to reduce tooth decay among vulnerable populations—particularly children and those covered by Medicaid. Curodont™ isn't just a new tool; it's a meaningful, science-driven advancement that is reshaping healthcare and setting a higher standard for dentistry where it's needed most." v Prof. Avijit Banerjee, Professor of Cariology & Operative Dentistry; Hon Consultant in Restorative Dentistry, Faculty of Dentistry, Oral & Craniofacial Sciences, King's College London, said, 'The scientific research into Curodont™ Repair technology has been well documented in reputable scientific peer-reviewed journals since the late 1990s. Multiple published clinical studies, including systematic meta-analyses, have provided evidence that, unlike conventional topical re-mineralizing agents which primarily act on the surface of the tooth, Curodont™ Repair can treat early decay throughout the depth of the lesion.' vi Prof. Ivo Krejci, University of Geneva, said: 'Curodont™ is no longer the future. It's the present and it should be part of the treatment spectrum in every modern dental practice.' vVARDIS's Curodont™ products are currently available in the U.S. and Europe and will continue to roll out globally. About Curodont™ Using a proprietary biomimetic formulation, Curodont™ is a groundbreaking clinically proven drill-free treatment for early tooth decay. It replicates and builds on the body's natural defenses, working together with minerals in the saliva to repair the damage done to the tooth in the early stages of tooth decay. Curodont™ is a non-invasive, drill-free solution: once the formula is applied, it diffuses through the enamel and repairs the missing parts of the tooth (lesions) with minerals from saliva by mimicking the way nature created teeth (biomimetic). The beauty of this product is that Curodont™ helps patients save the natural tooth structure without artificial filling materials. About vVARDIS AG vVARDIS is a Swiss high-growth healthcare company located in Zug, Switzerland that offers groundbreaking biomimetic, non-invasive solutions for dental professionals under the Curodont™ brand. Founded by Drs. Haley and Goly Abivardi, sisters, Swiss dentists, innovators, and awarded entrepreneurs, vVARDIS is the result of more than 25 years of research, paired with the commitment of its founders to make an impact on people's lives, especially the underserved. vVARDIS' mission is to expand access to novel approaches to the standard of care in dentistry with the purpose of improving oral health – the foundation for overall health. vVARDIS is backed by more than 25 years of science, 230 scientific publications, including meta-analysis, peer-reviewed clinical studies and a long-term peer-reviewed real-world evidence study demonstrating a success rate above 90 percent. It has been used in clinical practice for more than 10 years. Curodont™ is already mentioned in lectures at renowned universities as a standard of care for the treatment of early decay. and
Business Wire
14-05-2025
- Business
- Business Wire
Pearl Announces Global Collaboration with vVARDIS to Transform Early Detection and Proactive Treatment of Early Dental Decay
LOS ANGELES--(BUSINESS WIRE)-- Pearl, the global leader in dental AI solutions, today announced a collaboration with vVARDIS, a leader in innovative dental care products, to educate dental professionals about detecting and treating early stages of dental decay. The global collaboration brings together vVARDIS, which has biomimetic, drill-free early caries treatment products, Curodont™, and Pearl, which has an AI-powered real-time radiologic detection aid, Second Opinion, to deliver the message of advanced, non-invasive solutions for treating early dental decay. Pearl's AI solutions enable dental providers to accurately detect conditions such as decay or cavities at their earliest stages, ensuring a proactive approach to oral health. Beyond early condition detection, Pearl also builds patient trust by enhancing their understanding of dental imagery, leading to higher patient acceptance and more informed treatment decisions. vVARDIS' Curodont™ offers a drill-free brush-on solution to aid hydroxyapatite formation throughout the early decay, helping patients to preserve the natural tooth structure and helping to avoid invasive and costly fillings. Up to 80% of all patients have tooth decay in early stages 1. Curodont™ gives dental professionals the opportunity to treat these patients with a simple and fast topical application during the same visit it's detected, without the need for a new appointment. 'At Pearl, we are dedicated to enhancing and standardizing dental diagnostics by leveraging AI to simplify radiograph interpretation and improve patient communication,' said Ophir Tanz, CEO and founder of Pearl. 'Our collaboration with vVARDIS enables a comprehensive, internationally scalable approach to early intervention against dental decay, giving patients more options for an effective and proactive path to improved oral health.' 'Partnering with Pearl is a natural progression in our mission to provide innovative solutions for early stage dental decay,' said Jeremy Thomas, President, vVARDIS North America. 'This collaboration equips global dental professionals with modern tools to detect conditions sooner and provides a proven, non-invasive solution to help restore enamel health.' 'As both dentists and entrepreneurs, we are thrilled to finally have and offer a groundbreaking approach to treating early decay,' said Drs. Haley and Goly Abivardi, DMDs, Founders and Co-CEOs of vVARDIS. '34 million school hours are lost each year due to emergency dental care 2 and $45 billion in lost productivity annually from untreated oral disease in the United States 3,4. Dental professionals have been waiting for decades for a drill-free treatment that addresses the sub-clinical signs of caries in the same visit. With its seamless integration into existing workflows, we believe that Curodont™ has the potential to rapidly become the new standard of care for the treatment of early caries, broadening the scope of services offered and empowering dentists and hygienists to lead the way in the management of early caries, ultimately enhancing patient care.' About Pearl Pearl is an AI-driven company committed to enhancing patient care in dentistry. Founded in 2019 by a team with decades of experience developing successful, enterprise-grade computer vision solutions, Pearl introduced the first-ever FDA-cleared AI capable of reading and instantly identifying diseases in dental x-rays. With regulatory clearance in 120 countries, Pearl's AI assists dentists in making precise clinical decisions and effectively communicating with patients, thereby transforming the dental care experience worldwide. As dentistry's global AI leader, Pearl is committed to the ongoing innovation of robust, accessible AI tools that improve patient health outcomes and build greater trust in dental medicine. To request a demo, please visit About vVARDIS vVARDIS is an innovative Swiss healthcare company located in Zug, Switzerland that offers groundbreaking biomimetic, non-invasive solutions for dental professionals under the Curodont™ brand. Founded by Swiss dentists, innovators and awarded entrepreneurs, Dr. Haley Abivardi, DMD and Dr. Goly Abivardi, DMD, vVARDIS is the result of more than 25 years of research, paired with the commitment of its founders to make an impact on people's lives, including the underserved. vVARDIS' mission is to expand access to novel approaches to the standard of care in dentistry with the purpose of improving oral health – the foundation for overall health. vVARDIS science is backed by 25 years of research and more than 200 scientific publications, including meta-analysis, peer-reviewed clinical studies and a long-term peer-reviewed real-world evidence study, with hundreds of thousands of patients being treated successfully. For more information, visit vVARDIS at and
